Analyst Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Tarsus Pharmaceuticals and decreased the price target to $84.00 from $85.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors that highlight Tarsus Pharmaceuticals’ strong market performance and growth potential. The company reported impressive Q3 2025 earnings with a significant increase in Xdemvy net sales, surpassing both quarterly and yearly expectations. This growth is supported by an expanding prescriber base and robust payer coverage, ensuring broad access to their product.
Furthermore, Tarsus’s direct-to-consumer campaign has proven effective, significantly boosting traffic and awareness, which directly translates into prescription growth. The evolving prescribing behavior, with Xdemvy being used for a wider range of conditions, indicates a growing recognition of its clinical benefits. These factors, combined with a stable and expanding network of eye-care professionals prescribing Xdemvy, suggest a promising outlook for sustained growth, justifying the Buy rating.